Teresa Whalen, RPh | Chief Executive Officer
With more than 20 years in the healthcare industry as a biotech innovator, health technology leader, life sciences investor, and clinical pharmacist Teresa has a successful track record of bringing life-changing healthcare products to market.
As the CEO of CytoAgents, Teresa leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking solutions to combat persistent and potentially deadly strains of Influenza, COVID19 and other viruses. We are building a platform to revolutionize treatment for respiratory illnesses and viral epidemics.
We at CytoAgents are proud to be on the front lines in the battle against influenza, COVID19 and other viruses.
Jodi Craigo, PhD | Chief Science Officer
Jodi is a progressive, insightful, and strategic business-minded scientist with over 20 years of experience leading NIH and corporate-funded research programs. Jodi is a detail-oriented expert in microbial pathogenesis, host-pathogen interactions, microbial immunology, immune system monitoring, and diagnostic development with rigorous project management skills. Jodi played key roles in securing IP protections, evaluating and negotiating licensing agreements in cooperation with industrial collaborators.
Todd Lorenz, MD | Chief Medical Officer
Todd is an experienced clinical development professional with 15 years in upper management positions at Johnson & Johnson, Cor Therapeutics, Orexigen, Catalyst Biosciences and Corgentech. Also, as SVP, Clinical Development and Scientific Licensing at Portola Pharmaceuticals, Todd held primary responsibility for the Phase 3 program of betrixaban, involving 500 sites in 30 countries. Todd is also an advisor to the Stanford SPARK program and holds a BA in Chemistry from Case Western Reserve University and an MD from Case Western Reserve University, School of Medicine.
Roy Prieb | Chief Financial Officer
Roy Prieb is an entrepreneur with over 20 years of experience in building innovative technology and life sciences companies. Most recently, he was a co-founder and director of Kleo Pharmaceuticals, a synthetic immunotherapy company spun out from Yale University. He served as the company's COO/CFO overseeing non-R&D functions including finance, business development, human resources, IP management, and fund raising. Roy worked as a management consultant with Boston Consulting Group. He received his BA from Harvard College and MBA from Wharton Business School.
Dr. Michael Ison, MD, MS | Director, Transplant Infectious Disease Service NorthWestern
Dr. Ison received his BA at Grinnell College in Grinnell, Iowa. He then received his MD at the University of South Florida College of Medicine followed later by an MS in Health Evaluation Sciences at the University of Virginia. He completed his Internal Medicine training at Oregon Health Sciences University in Portland, OR, and Infectious Diseases training at the University of Virginia, and an additional year of Transplant Infectious Diseases training at the Massachusetts General Hospital. Specialties: Transplant and Immunocompromised Host Infectious Diseases.
Dr. Paul Thomas, PhD | St. Jude Children’s Research Hospital
Dr. Thomas received his PhD, Immunology and Infectious Disease from the Harvard T.H. Chan School of Public Health. Paul’s research program is focused on understanding how innate and adaptive immunity determine disease outcomes following influenza virus infection in murine and human experimental systems. Through his work immune signatures predictive of severe disease and poor clinical outcome in patients infected with influenza virus have been identified. Paul’s lab is part of the Center for Excellence for Influenza Research and Surveillance at St. Jude.
Dr. Albert Osterhaus, PhD | Scientific Director at Viroclinics Biosciences BV | Amsterdam, Netherlands
As a veterinarian with a PhD in Virology from Utrecht University, Ab Osterhaus became head of the Department of Immunobiology at RIVM in The Netherlands. As professor of Virology at Utrecht University and professor and head of the Virology Department of Erasmus Medical Centre, Rotterdam, he developed a long track record as PI of numerous international scientific projects, guiding a multidisciplinary team of over 100 “Viroscience” colleagues studying human and animal virus infections. More than 50 human and animal viruses were discovered (e.g. human metapneumovirus, SARS-CoV, MERS-CoV, several influenza viruses), their pathogenesis elucidated, and intervention strategies developed. He helped national and international health authorities like WHO, to combat emerging human infections like SARS, MERS, H5N1 and H7N7 avian influenza. He established several spin-out companies. Currently he is Professor and Founding Director of RIZ at the University of Veterinary Medicine Hannover and Chair of the European Working Group on Influenza (ESWI) and of the International One Health Platform (OHP).
BOARD OF DIRECTORS
Teresa Whalen, RPh | Chief Executive Officer and President
Catherine V. Mott | Founder, CEO, Managing Partner Blue Tree Capital Group
Catherine is the founder and CEO of BlueTree Capital Group and BlueTree Allied Angels. Catherine is the past Chairman of the Angel Capital Education Foundation, Chairman of the Board of the Angel Capital Association, on the SEC Advisory Committee on Small and Emerging Companies.
Catherine had founded Synergetic Sales Performance Group, and Indigo Capital Development, LLC. In 2002, she was recognized as one of Pennsylvania’s 50 Best Women in Business. Previously, Catherine worked 17 years in corporate banking management where she served in senior management roles.
Anthony McCarley | CEO, Business Coach, Executive Coach, Keynote Speaker
Anthony is founder of McCarley International which has a mission of guiding business owners, executives, and organizations who are driven to truly accomplish great things. McCarley International specializes in working with companies experiencing significant change and transition – whether by design or circumstance. Anthony has over 30 years of experience as a senior executive with two Global 100 companies and two start-up companies. Anthony walks the walk and talks the talk.
Anthony became a Triple Crown marathon swimmer in 2014 by crossing the English Channel, circumnavigating Manhattan Island, and crossing the Catalina Channel in southern California. He completed the three marathon swims in less than one year. He was named a 2014 Global Marathon Swimming Federation Award finalist in the Most Impressive Overall Year category.